Galanin coexists with acetylcholine in medial septal neurons projecting to the ventral hippocampus, a projection thought to modulate memory functions. Neurochemical lesions of the nucleus basalis-medial septal area in rats impaired choice accuracy on a delayed alternation t-maze task. Acetylcholine (7.5 or 10 ,sg intraventricularly or 1 ,.g microinjected into the ventral hippocampus) significantly improved performance in the lesioned rats. Atropine (5 mg/kg intraperitoneally or 10 ,.g intraventricularly), but not mecamylamine (3 mg/kg intraperitoneally or 20 ,ug intraventricularly), blocked this action of acetylcholine, suggesting involvement of a muscarinic receptor. Galanin (100-500 ng intraventricularly or 200 ng into the ventral hippocampus) attenuated the ability of acetylcholine to reverse the deficit in working memory in the lesioned rats. The antagonistic interaction between galanin and acetylcholine suggests that endogenous galanin may inhibit cholinergic function in memory processes, particularly in pathologies such as Alzheimer disease that involve degeneration of basal forebrain neurons.
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Galanin (GAL) is a 29-amino acid peptide (1) localized in many regions of the mammalian central nervous system (2) (3) (4) (5) . Immunohistochemical studies revealed the coexistence of GAL and choline acetyltransferase (ChAT), the synthetic enzyme for acetylcholine (ACh), in the medial septal nucleus and nucleus basalis/diagonal band complex of primates (6, 7) .
In the rat, GAL coexists with ACh in the medial septal neurons projecting to the ventral hippocampus but not in the nucleus basalis neurons projecting to the cerebral cortex (8, 9) . The localization of this peptide in the septo-hippocampal pathway, and the high density of GAL binding sites labeled with 1251I-labeled GAL in the ventral hippocampus (10) , raise the possibility of a functional role for GAL in memory processes. To investigate the functional significance of the GAL-ACh coexistence, rats were microinjected with GAL, ACh, GAL plus ACh, or saline before behavioral testing with a t-maze delayed alternation task, in which performance was disrupted by lesions of the nucleus basalis-medial septal area (11) .
MATERIALS AND METHODS
Male Sprague-Dawley rats, 200 g (starting weight), were housed in a temperature and humidity controlled vivarium, with lights on from 0700 to 1900. Lesions of the nucleus basalis magnocellularis (NBM) and medial septal area (MSA) were performed according to the methods of Wenk and coworkers (12) . Briefly, rats were anesthetized with sodium pentobarbital (50 mg/kg, i.p.) and intracerebrally microinjected through 31- 10 ,ug as compared to ACh at 10 ,ug; P < 0.01, GAL at 50 ng plus ACh at 10 ,g and ACh at 10 ,ug as compared to saline).
As shown in Fig. 4 GAL administered ivt by itself had no effect on performance in delayed alternation. Doses of 100 ng, 200 ng, 500 ng, and 1 ,ug, chosen to test the upper range of GAL doses that antagonized ACh, had no significant effects in either NBM-MSA lesioned or sham control rats. Data are presented as mean + SEM (n = 5 for each dose of each treatment).
ory in monkeys (19) (20) (21) (22) (23) (24) (25) . Cholinergic agonists, cholinesterase inhibitors, and hippocampal grafts of cholinergic neurons have been reported to restore memory function after these lesions and to improve memory function in normal rats and mice (26) (27) (28) (29) (30) . Our findings demonstrate that ACh infusion ivt or intrahippocampally can ameliorate a NBM-MSA lesioninduced memory deficit for a short period oftime and that this treatment can be effectively repeated in the same animal.
The present data suggest that GAL acts as an inhibitory modulator of cholinergic function on retention of a memory task in rats. When administered alone, GAL had neither an inhibitory nor a potentiating effect on working memory in sham control or NBM-MSA lesioned rats in the present paradigm. When administered in combination with ACh, GAL partially antagonized the ability of ACh to reverse the memory deficit in lesioned rats. These results support an interpretation that the NBM-MSA lesion induces an increased sensitivity to ACh and GAL.
Alternatively, the lack of effect of ACh and GAL in sham control rats may be a function of the behavioral paradigm. Since sham control rats are performing at maximal levels in 11, v the present paradigm, ACh cannot further improve performance. The lack of effect of GAL in sham control rats may relate to other, possibly competing physiological actions of GAL (31) . For example, centrally administered GAL has been shown to increase feeding behavior (32) . Increased motivation for a food reward could counteract inhibitory effects of GAL on delayed alternation, which is a food rewarded task. In another behavioral paradigm, employing normal rats in a Morris swim maze task, Sundstrom et al. (33) report that high doses of GAL (1 ug (10) . These regions may all contribute to retention and retrieval of spatial memory in the rat. However, the finding that GAL blocks the behavioral actions of ACh when microinjected into the ventral hippocampus suggests that the septo-hippocampal pathway, wherein ACh and GAL coexist, is one site of functional interaction.
Our behavioral data, demonstrating an inhibitory action of GAL on ACh in a working memory paradigm, is consistent with biochemical studies, demonstrating an inhibitory effect of GAL on carbachol-stimulated phosphatidylinositol turnover in the ventral hippocampus of the rat (36) . In addition, GAL at 10 ,g ivt has been shown to inhibit scopolamine-or potassium-evoked release of [3H]ACh in the ventral hippocampus (37) . Physiological studies have demonstrated that GAL antagonizes cholinergic synaptic transmission in the myenteric plexus of the guinea pig small intestine (38) and inhibits spontaneous synaptic potentials of dorsal horn neurons in the rat spinal cord (39) . From these several lines of evidence, it appears that endogenous GAL could serve as an inhibitor of cholinergic activity. In this case of coexistence of a neuropeptide with a "classical" neurotransmitter, the function of the peptide may be to provide negative feedback, possibly to limit both the maximal release and the postsynaptic effects of ACh.
The coexistence of GAL and ACh in neurons of the NBM has been described in human brain (40) . The role of GAL within cholinergic neurons during the progression of Alzheimer disease remains to be elaborated. One prediction, as hypothesized by Hokfelt et al. (41) , suggests that as many cholinergic neurons degenerate during the disease process, the remaining cholinergic neurons may compensate by inProc. Natl. Acad. Sci. USA 85 (1988) Iv ell, creasing their firing rate. Higher firing rates could result in greater release of GAL, which could then prevent the actions of the remaining ACh (41) . Our finding that the inhibitory action of GAL occurred only in rats lesioned in the NBM-MSA supports an interpretation that loss of some cholinergic neurons changes the function of the remaining cholinergic neurons or their receptors. Thus, the inhibitory actions of GAL on cholinergic function may be greatest in disease states in which cholinergic neurons are damaged or degenerating. In addition, in a clinical study of GAL in Alzheimer patients, by examining cerebrospinal fluid concentration as a measure of GAL release throughout the brain, no decrease in GAL levels was found in individuals with advanced Alzheimer disease, as compared with age-matched controls (42) . Although the concentration of GAL in cerebrospinal fluid is the summation of all brain GAL released, rather than a specific measure of GAL in ventral forebrain neurons, it is interesting to speculate that GAL-containing cholinergic neurons might survive to a greater extent than cholinergic neurons that do not contain GAL-i.e., the peptide serves a protective or trophic function. In the extreme stage of Alzheimer disease, in which very few cholinergic neurons remain, the inhibitory actions of GAL on cholinergic function could be particularly detrimental. An antagonist of GAL might prevent the postulated inhibitory actions of endogenous GAL on cholinergic function, which possibly suggests an approach to the development of treatments for some of the cognitive dysfunctions manifested in the symptomology of Alzheimer disease.
